Enhancing Fraction in Glioma and Its Relationship to the Tumoral Vascular Microenvironment: A Dynamic Contrast-Enhanced MR Imaging Study

References

1. 1.↵
   1. Evelhoch JL

   . Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999; 10: 254–59

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Roberts C,
   2. Issa B,
   3. Stone A,
   4. et al

   . Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 2006; 23: 554–63

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Tofts PS

   . Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7: 91–101

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Aronen HJ,
   2. Gazit IE,
   3. Louis DN,
   4. et al

   . Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191: 41–51

   PubMedWeb of Science
5. 5.↵
   1. Aronen HJ,
   2. Glass J,
   3. Pardo FS,
   4. et al

   . Echo-planar MR cerebral blood volume mapping of gliomas: clinical utility. Acta Radiol 1995; 36: 520–28

   Abstract/FREE Full Text
6. 6.↵
   1. Aronen HJ,
   2. Pardo FS,
   3. Kennedy DN,
   4. et al

   . High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: 2189–200

   Abstract/FREE Full Text
7. 7.↵
   1. Knopp EA,
   2. Cha S,
   3. Johnson G,
   4. et al

   . Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999; 211: 791–98

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Lam WW,
   2. Chan KW,
   3. Wong WL,
   4. et al

   . Pre-operative grading of intracranial glioma. Acta Radiol 2001; 42: 548–54

   FREE Full Text
9. 9.↵
   1. Law M,
   2. Yang S,
   3. Babb JS,
   4. et al

   . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004; 25: 746–55

   Abstract/FREE Full Text
10. 10.↵
    1. Law M,
    2. Yang S,
    3. Wang H,
    4. et al

    . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24: 1989–98

    Abstract/FREE Full Text
11. 11.↵
    1. Lev MH,
    2. Ozsunar Y,
    3. Henson JW,
    4. et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004; 25: 214–21

    Abstract/FREE Full Text
12. 12.↵
    1. Sadeghi N,
    2. Salmon I,
    3. Decaestecker C,
    4. et al

    . Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 2007; 28: 455–61

    Abstract/FREE Full Text
13. 13.↵
    1. Patankar TF,
    2. Haroon HA,
    3. Mills SJ,
    4. et al

    . Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? AJNR Am J Neuroradiol 2005; 26: 2455–65

    Abstract/FREE Full Text
14. 14.↵
    1. Ludemann L,
    2. Grieger W,
    3. Wurm R,
    4. et al

    . Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging 2005; 23: 833–41

    CrossRefPubMed
15. 15.↵
    1. Cha S,
    2. Tihan T,
    3. Crawford F,
    4. et al

    . Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005; 26: 266–73

    Abstract/FREE Full Text
16. 16.↵
    1. Law M,
    2. Brodsky JE,
    3. Babb J,
    4. et al

    . High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging 2007; 25: 1113–19

    CrossRefPubMed
17. 17.↵
    1. Jenkinson MD,
    2. Smith TS,
    3. Joyce KA,
    4. et al

    . Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006; 48: 703–13. Epub 2006 Aug 26

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Cha S,
    2. Yang L,
    3. Johnson G,
    4. et al

    . Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol 2006; 27: 409–17

    Abstract/FREE Full Text
19. 19.↵
    1. Provenzale JM,
    2. Wang GR,
    3. Brenner T,
    4. et al

    . Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002; 178: 711–16

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Roberts HC,
    2. Roberts TP,
    3. Brasch RC,
    4. et al

    . Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: 891–99

    Abstract/FREE Full Text
21. 21.↵
    1. Cao Y,
    2. Tsien CI,
    3. Nagesh V,
    4. et al

    . Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006; 64: 876–85

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Law M,
    2. Oh S,
    3. Johnson G,
    4. et al

    . Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006; 58: 1099–107

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Mills SJ,
    2. Patankar TA,
    3. Haroon HA,
    4. et al

    . Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006; 27: 853–58

    Abstract/FREE Full Text
24. 24.↵
    1. Law M,
    2. Oh S,
    3. Babb JS,
    4. et al

    . Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology 2006; 238: 658–67

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Law M,
    2. Young RJ,
    3. Babb JS,
    4. et al

    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008; 247: 490–98

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Jayson GC,
    2. Parker GJ,
    3. Mullamitha S,
    4. et al

    . Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005; 23: 973–81. Epub 2004 Oct 4

    Abstract/FREE Full Text
27. 27.↵
    1. Mullamitha SA,
    2. Ton NC,
    3. Parker GJ,
    4. et al

    . Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 2007; 13: 2128–35

    Abstract/FREE Full Text
28. 28.↵
    1. O'Connor JP,
    2. Jayson GC,
    3. Jackson A,
    4. et al

    . Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. Clin Cancer Res 2007; 13: 6130–35

    Abstract/FREE Full Text
29. 29.↵
    1. Mills SJ,
    2. Soh C,
    3. O'Connor JP,
    4. et al

    . Tumour enhancing fraction (EnF) in glioma: relationship to tumour grade. Eur Radiol 2009; 19: 1489–98

    CrossRefPubMed
30. 30.↵
    1. Louis DN,
    2. Ohgaki H,
    3. Wiestler OD,
    4. et al

    . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97–109. Epub 2007 Jul 6

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Thompson G,
    2. Cain J,
    3. Jackson A,
    4. et al

    . Interobserver agreement for cerebral glioma volumetrics on conventional MR imaging. In: Proceedings of the 16th Annual Scientific Meeting and Exhibition of the International Society of Magnetic Resonance in Medicine, Toronto, Ontario, Canada. May 3–9, 2008
32. 32.↵
    1. Parker GJM,
    2. Jackson A,
    3. Waterton JC,
    4. et al

    . Automated arterial input function extraction for T1-weighted DCE-MRI. In: Proceedings of the 11th Annual Scientific Meeting and Exhibition of the International Society of Magnetic Resonance in Medicine, Toronto, Ontario, Canada. July 10–16, 2003
33. 33.↵
    1. Parker GJM,
    2. Buckley DL

    . Tracer Kinetic Modelling for T1-Weighted DCE-MRI. Berlin: Springer-Verlag; 2005: 81–92
34. 34.↵
    1. Norden AD,
    2. Young GS,
    3. Setayesh K,
    4. et al

    . Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779–87

    CrossRef
35. 35.↵
    1. Sathornsumetee S,
    2. Reardon DA,
    3. Desjardins A,
    4. et al

    . Molecularly targeted therapy for malignant glioma. Cancer 2007; 110: 13–24

    CrossRefPubMedWeb of Science